BRPI0407833A - anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio - Google Patents

anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio

Info

Publication number
BRPI0407833A
BRPI0407833A BRPI0407833-0A BRPI0407833A BRPI0407833A BR PI0407833 A BRPI0407833 A BR PI0407833A BR PI0407833 A BRPI0407833 A BR PI0407833A BR PI0407833 A BRPI0407833 A BR PI0407833A
Authority
BR
Brazil
Prior art keywords
human
antibodies
human monoclonal
disorder
treating
Prior art date
Application number
BRPI0407833-0A
Other languages
English (en)
Inventor
Jan G J Van De Winkel
Marcus Antonius Van Dijk
Janine Schuurman
Arnout F Gerritsen
Ole D M Sc Baadsgaard
Jorgen Petersen
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/374,932 external-priority patent/US7329405B2/en
Application filed by Genmab As filed Critical Genmab As
Publication of BRPI0407833A publication Critical patent/BRPI0407833A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)

Abstract

"ANTICORPO MONOCLONAL HUMANO ISOLADO,E, MéTODO DE TRATAR OU PREVENIR UM DISTúRBIO". Anticorpos monoclonais humanos isolados que especificamente se ligam a IL-15 (por exemplo, IL-15 humana), e composições e moléculas com base em anticorpo relacionadas, são divulgadas. Os anticorpos humanos podem ser produzidos em um transfectoma ou em um animal transgênico não humano, por exemplo, um camundongo transgênico, capaz de produzir isótipos múltiplos de anticorpos monoclonais humanos que passam por recombinação V-D-J e comutação de isótipo. Também divulgadas são as composições farmacêuticas compreendendo os anticorpos humanos, animais transgênicos não humanos, e hibridomas que produzem os anticorpos humanos, e métodos terapêuticos e de diagnóstico para usar os anticorpos humanos.
BRPI0407833-0A 2003-02-26 2004-02-25 anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio BRPI0407833A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/374,932 US7329405B2 (en) 2001-08-23 2003-02-26 Human antibodies specific for interleukin 15 (IL-15)
US10/379,741 US7247304B2 (en) 2001-08-23 2003-03-05 Methods of treating using anti-IL-15 antibodies
PCT/IB2004/000484 WO2004076620A2 (en) 2003-02-26 2004-02-25 Human antibodies specific for interleukin 15 (il-15)

Publications (1)

Publication Number Publication Date
BRPI0407833A true BRPI0407833A (pt) 2006-02-14

Family

ID=32930206

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407833-0A BRPI0407833A (pt) 2003-02-26 2004-02-25 anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio

Country Status (14)

Country Link
US (3) US7247304B2 (pt)
EP (1) EP1597283A2 (pt)
KR (1) KR20050103306A (pt)
AU (1) AU2004215120B8 (pt)
BR (1) BRPI0407833A (pt)
CA (1) CA2516378A1 (pt)
GB (1) GB2414732B (pt)
HU (1) HUP0500951A2 (pt)
MX (1) MXPA05008678A (pt)
NO (1) NO20054078L (pt)
NZ (1) NZ542418A (pt)
PL (1) PL378276A1 (pt)
TW (1) TWI350290B (pt)
WO (1) WO2004076620A2 (pt)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
CA2584211C (en) * 2004-10-22 2014-07-08 Amgen Inc. Methods for refolding of recombinant antibodies
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
AR059065A1 (es) * 2006-01-23 2008-03-12 Amgen Inc Metodos para modular el contenido de manosa de las proteinas recombinantes
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
CA2698809C (en) * 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
MX2010011955A (es) * 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2490957B1 (en) 2009-10-23 2016-11-23 Amgen, Inc Vial adapter and system
BR112012031121B1 (pt) 2010-06-07 2022-09-27 Amgen Inc Dispositivo de distribuição de drogas, kit e método de operar um dispositivo de distribuição de droga utilizável
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
NO2582728T3 (pt) 2010-06-15 2018-01-20
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
SI2699293T1 (sl) 2011-04-20 2019-05-31 Amgen Inc. Avtoinjekcijski aparat
JP6323718B2 (ja) 2011-05-17 2018-05-16 ザ ロックフェラー ユニバーシティー ヒト免疫不全ウイルスを無毒化する抗体、およびその使用方法。
KR102222187B1 (ko) 2011-10-14 2021-03-03 암젠 인크 주사기 및 어셈블리 방법
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
US20150290390A1 (en) 2012-11-21 2015-10-15 Amgen Inc. Drug delivery device
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
TWI639453B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
EP3831427A1 (en) 2013-03-22 2021-06-09 Amgen Inc. Injector and method of assembly
PL3060275T3 (pl) 2013-10-24 2019-12-31 Amgen Inc. Wstrzykiwacz i sposób montażu
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3139977B1 (en) 2014-05-07 2021-02-17 Amgen Inc. Autoinjector with shock reducing elements
IL281354B2 (en) 2014-06-03 2024-06-01 Amgen Inc Devices and methods to assist the user of a drug delivery device
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
JP6766040B2 (ja) 2014-10-14 2020-10-07 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP4209499A1 (en) 2015-08-13 2023-07-12 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
AU2017205185B2 (en) * 2016-01-07 2022-03-31 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
JP2019521981A (ja) * 2016-06-15 2019-08-08 アムジエン・インコーポレーテツド セリアック病、非セリアックグルテン過敏症及び難治性セリアック病を治療するための方法及び組成物
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
IL267113B1 (en) * 2016-12-21 2024-05-01 Cephalon Llc Antibodies that bind specifically to human IL-15 and their uses
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
ES2959935T3 (es) 2017-03-28 2024-02-29 Amgen Inc Sistema y método de vástago de émbolo y conjunto de jeringa
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
IL273323B1 (en) 2017-10-09 2024-06-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
EP3703779A1 (en) 2017-11-03 2020-09-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
MX2021003491A (es) 2018-10-05 2021-06-18 Amgen Inc Dispositivo de administracion de farmacos con indicador de dosis.
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0463151T3 (da) * 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
JPH10508737A (ja) * 1994-11-15 1998-08-25 テレフオンアクチーボラゲツト エル エム エリクソン 移動体通信システムのセクタ化した無線アクセス装置に対する動的チャネル割り当て装置
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
WO1996031230A1 (fr) * 1995-04-02 1996-10-10 Chugai Seiyaku Kabushiki Kaisha Composition medicinale pour guerir la thrombopenie
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5660824A (en) * 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
JP2001502521A (ja) * 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
DK0932417T3 (da) * 1996-10-17 2003-04-14 Immunomedics Inc Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
ATE295736T1 (de) 1997-02-21 2005-06-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
EP0972445B1 (en) 1997-02-28 2006-07-05 Kirin Beer Kabushiki Kaisha Chimeric mice that express a human antibody
US5798966A (en) * 1997-03-31 1998-08-25 Intel Corporation Flash memory VDS compensation techiques to reduce programming variability
GB9814892D0 (en) 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
WO2001002003A1 (en) 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
EP1349873B1 (en) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
EA014802B1 (ru) 2001-08-23 2011-02-28 Генмаб А/С АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies

Also Published As

Publication number Publication date
US7247304B2 (en) 2007-07-24
AU2004215120B8 (en) 2011-08-11
NZ542418A (en) 2008-07-31
US7597892B2 (en) 2009-10-06
NO20054078D0 (no) 2005-09-01
AU2004215120A8 (en) 2011-08-11
GB0518243D0 (en) 2005-10-19
US20040071702A1 (en) 2004-04-15
PL378276A1 (pl) 2006-03-20
TWI350290B (en) 2011-10-11
US7585961B2 (en) 2009-09-08
GB2414732B (en) 2007-01-03
AU2004215120B2 (en) 2011-07-28
NO20054078L (no) 2005-11-02
KR20050103306A (ko) 2005-10-28
US20080166802A1 (en) 2008-07-10
WO2004076620A3 (en) 2004-12-23
WO2004076620A2 (en) 2004-09-10
EP1597283A2 (en) 2005-11-23
GB2414732A (en) 2005-12-07
AU2004215120A1 (en) 2004-09-10
MXPA05008678A (es) 2005-11-04
HUP0500951A2 (en) 2007-07-30
TW200500378A (en) 2005-01-01
US20080166347A1 (en) 2008-07-10
WO2004076620A9 (en) 2004-10-21
CA2516378A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
BRPI0407833A (pt) anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio
LTPA2021514I1 (pt)
BRPI0210405B8 (pt) anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
ATE531390T1 (de) Interleukin-15-(il-15-)spezifische menschliche antikörper
BR0316282A (pt) Anticorpo humano isolado, hibridoma, transfectoma, célula hospedeira eucariótica ou procariótica, animal não humano ou planta transgênica, método para produzir um anticorpo monoclonal humano, composição, imunoconjugado, molécula biespecìfica ou multiespecìfica, método para inibir o desenvolvimento e/ou a proliferação de uma célula que expressa cd25, método para eliminar uma célula que expressa cd25, método para tratar ou evitar um distúrbio que envolve as células que expressam cd25, método e conjunto de diagnóstico para detectar a presença de antìgeno cd25 ou uma célula que expressa cd25, vetor de expressão, anticorpo anti-idiotìpico, e, uso do mesmo
BR0307216A (pt) Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
ATE531731T1 (de) Humane monoklonale antikörper gegen den epidermal-growth-factor-rezeptor (egfr)
DE60037896D1 (de) Menschliche antikörper gegen her2/neu
BR0306808A (pt) Anticorpos monoclonais humanos contra cd30
DE60031279D1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
ATE527278T1 (de) Humane monoklonale antikörper gegen interleukin 8 (il-8)
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.